If you are wondering whether Madrigal Pharmaceuticals at around US$480 a share is still priced attractively, you are not alone. This article focuses squarely on what that price might mean for value focused investors.
The stock has had a mixed run, with a 46.4% return over 1 year and a very large 5 year gain, while shorter term moves have been weaker, including a 4.2% decline over 7 days, 19.8% over 30 days, and 19.1% year to date.
Recent news coverage has centered on Madrigal’s position in the pharmaceuticals and biotech space and the market’s reaction to company specific developments such as clinical progress and regulatory milestones. This backdrop helps explain why the share price has seen both strong multi year returns and more…
